Digital platform for hypertension management launches in Europe
Ella Day | June 13, 2025 | News story | Business Services, Technical Consultancy | Chronic Diseases, HealthTech, Newel Health, digital platform, high blood pressure, hypertension management, hypertension therapy
Newel Health, a European healthtech company specialising in digital medical devices, has announced that Amicomed, its digital platform for hypertension management, has received CE certification as a class IIa medical device under the European medical device regulation (MDR). This positions Amicomed as a leading digital therapy candidate and, in collaboration with stakeholders, Newel intends to reshape hypertension management in Europe.
The Amicomed platform helps patients self-manage their daily blood pressure by offering personalised feedback based on real-world data. Features include medication reminders, personalised dietary recommendations and structured summaries, complementing antihypertensive therapies like lifestyle modification and medication. Designed to be highly accessible, it is compatible with Apple Health, Google Fit, and major Bluetooth-enabled blood pressure monitors. It also accepts manual data entry.
The service will be distributed through multiple channels, including direct-to-consumer, health insurance partners, digital pharmacies and public health systems. Pilot programmes are underway in several European countries.
Newel Health creates software-based therapeutics that address chronic diseases, of which patient behaviour and data are integral to clinical outcomes. Its solutions have been validated in population health programmes for cardiovascular risk monitoring and chronic care optimisation, as well as in digital insurance models.
“The MDR certification enables us to bring Amicomed to millions of individuals across Europe and to pursue scalable growth in partnership with public and private healthcare stakeholders,” commented Ervin Ukaj, CEO of Newel Health.
Ella Day
13/6/25
Related Content
Lilly reports positive results from trial of obesity candidate
Eli Lilly and Company (Lilly) has announced topline results from its phase 3 ATTAIN-1 trial, …
Medable unveils oncology trial platform aimed at reducing logistical hurdles
Clinical trial technology provider, Medable, has launched a digital platform designed to support oncology clinical …
Pfizer launches Healthcare Hub to support healthtech startups
Pfizer has announced the launch of ‘Pfizer Healthcare Hub: London’, a project that aims to …
